Share Price, page-15084

Significant concerns discussed in the report re. clinical value of Trofinetide, clinical trial methodology, endpoints chosen, side effect burden and cost to the taxpayer in socially funded health care system.

I found the most concerning line to be:

"A price reduction of more than 98% would be
required for trofinetide plus BSC to be considered cost-effective at a willingness-to-pay threshold of $100,000 per QALY gained."

A jargon heavy public health way to say based on the panel's economic analysis, the cost of the drug isn't justified by the assessed clinical benefit.